Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomesAndrew Leonard Laccetti, Matthew T. Campbell, Eric Jonasch et al.|Cancer Medicine|2021Cited by 19
A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current LiteratureMinas P. Economides, Matthew T. Campbell, Amishi Y. Shah et al.|Frontiers in Endocrinology|2020Cited by 18
Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial CarcinomaMehrad Adibi, Matthew T. Campbell, Barrett Z. McCormick et al.|Clinical Genitourinary Cancer|2021Cited by 14